Spots Global Cancer Trial Database for l19
Every month we try and update this database with for l19 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radioimmunotherapy With 131I-L19SIP in Patients With Cancer | NCT01242943 | Patients With C... | 131I-L19SIP Rad... | 18 Years - 75 Years | Philogen S.p.A. | |
| L19TNFα in Patients With Advanced Solid Tumors | NCT01253837 | Solid Tumors Colorectal Canc... | L19TNFa | 18 Years - | Philogen S.p.A. | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC) | NCT01124812 | Non Small Cell ... | 131I-L19SIP Rad... | 18 Years - | Philogen S.p.A. | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours | NCT01058538 | Advanced Solid ... | L19IL2 | 18 Years - | Philogen S.p.A. | |
| A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours | NCT01058538 | Advanced Solid ... | L19IL2 | 18 Years - | Philogen S.p.A. | |
| Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients | NCT01198522 | Pancreatic Canc... | L19IL2 monoclon... | 18 Years - 70 Years | Philogen S.p.A. | |
| 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors | NCT01125085 | Brain Metastase... | 131I-L19SIP Rad... | 18 Years - | Philogen S.p.A. | |
| L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours | NCT02076620 | Advanced Solid ... Sarcoma, Breast... | L19TNFα Doxorubicin | 18 Years - | Philogen S.p.A. | |
| Radioimmunotherapy With 131I-L19SIP in Patients With Cancer | NCT01242943 | Patients With C... | 131I-L19SIP Rad... | 18 Years - 75 Years | Philogen S.p.A. | |
| Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients | NCT01198522 | Pancreatic Canc... | L19IL2 monoclon... | 18 Years - 70 Years | Philogen S.p.A. | |
| A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours | NCT01058538 | Advanced Solid ... | L19IL2 | 18 Years - | Philogen S.p.A. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
